The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...

The FDA also recommends that prescribed users reduce their caloric intake and increase their exercise The weight loss drug ...

GLP-1 medications like Semaglutide (found in Ozempic and Wegovy) and Tirzepatide (found in Mounjaro) mimic the body’s natural ...

The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.

The U.S. Food and Drug Administration announced Thursday that the shortage of tirzepatide — the active ingredient in Eli ...

If you’re starting a weight loss journey, you might have stumbled upon tirzepatide — the drug approved by the FDA (U.S. Food and Drug Administration) under the brand names Mounjaro and Zepbound.

The U.S. Food and Drug Administration said on Thursday there was no longer a shortage of Eli Lilly’s (LLY.N) blockbuster ...

Semaglutide and Tirzepatide, both FDA-approved medications, are glucagon-like peptide-1 (GLP-1) receptor agonists that have gained recognition for their efficacy in supporting significant weight loss.

The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli ...